Skip to main content
Premium Trial:

Request an Annual Quote

And We Thought They Were Joined at the Hip

23andMe's Linda Avey is leaving the personal genomics company to start a nonprofit foundation, reports TechCrunch. According to an email Avey sent to employees, her new foundation will focus on Alzheimer's disease research and "will leverage the research platform we've built at 23andMe — the goal is to drive the formation of the world's largest community of individuals with a family history of Alzheimer's, empower them with their genetic information and track their brain health using state-of-the-art tools," the email says. Avey adds that this decision was in part based on her father-in-law suffering from Alzheimer's disease. Avey co-founded 23andMe with Anne Wojcicki in 2006.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.